

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**金威医疗集团有限公司**

Good Fellow Healthcare Holdings Limited

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 8143)**

**(1) CHANGE OF EXECUTIVE DIRECTOR;  
(2) CHANGE IN COMPOSITION OF BOARD COMMITTEE;  
AND  
(3) CHANGE OF AUTHORISED REPRESENTATIVE UNDER  
THE GEM LISTING RULES AND AUTHORIZED REPRESENTATIVE  
UNDER THE COMPANIES ORDINANCE**

The Board hereby announces the following changes with effect from 22 August 2023:

1. Mr. Zheng Gang has resigned from his positions as an executive Director and a member of the Remuneration Committee and ceased to act as an authorised representative of the Company under Rule 5.24 of the GEM Listing Rules and an authorized representative of the Company to accept service of process or notice on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance;
2. Mr. Wu Qiyu has been appointed as an executive Director and a member of the Remuneration Committee; and
3. Mr. Lam Williamson has been appointed as an authorised representative of the Company under Rule 5.24 of the GEM Listing Rules and an authorized representative of the Company to accept service of process or notice on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance.

The board (the “**Board**”) of directors (the “**Director(s)**”) of Good Fellow Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces the following changes with effect from 22 August 2023.

## **RESIGNATION OF EXECUTIVE DIRECTOR**

Mr. Zheng Gang (“**Mr. Zheng**”) has resigned from his position as an executive Director and a member of the remuneration committee (the “**Remuneration Committee**”) of the Company with effect from 22 August 2023 as he would like to devote more time to his personal commitment.

Mr. Zheng has confirmed that he has no disagreement with the Board and that there is no matter relating to his resignation that needs to be brought to the attention of the shareholders (the “**Shareholders**”) of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its sincere gratitude to Mr. Zheng for his valuable contributions to the Company during his tenure of office.

## **APPOINTMENT OF EXECUTIVE DIRECTOR**

The Board is pleased to announce that following the resignation of Mr. Zheng, Mr. Wu Qiyong (“**Mr. Wu**”) has been appointed as an executive Director and a member of the Remuneration Committee with effect from 22 August 2023.

The biographical details of Mr. Wu are set out as follows:

Mr. Wu, aged 30, possesses profound expertise in business management, strategic planning and risk management. Mr. Wu obtained a Bachelor of Business (Banking and Finance) from the Monash University in 2016 and a Master of Business Administration from the same university in 2022.

From 2016 to 2020, Mr. Wu served as an investment manager at Cornerstone Capital Investment Group Pty Ltd, leading multiple commercial real estate projects involving retirement and medical assets, monitoring compliance and conducting risk control for those projects. From 2021 to 2022, Mr. Wu was a member of the management team at Lunghealth Medtech Company Limited, spearheading the strategic rollout of the magnetic navigation bronchoscope system in the Chinese market, ensuring the safety of the product and overseeing the compliance with the relevant laws and regulations. In December 2022, Mr. Wu founded Dynamiq Advisory Pte Ltd (“**Dynamic Advisory**”) and has been the chief executive officer Dynamic Advisory thereafter, providing its clients with comprehensive corporate services, including but not limited to compliance and risk management services.

Mr. Wu has entered into a service agreement with the Company for a term of three years (the “**Term**”) renewable automatically upon expiry of the Term, unless terminated by a three (3)-month prior written notice by either party after the expiry of the Term. Mr. Wu is subject to retirement by rotation and re-election at the first annual general meeting of the Company after his appointment pursuant to the articles of association (the “**Articles**”) of the Company and thereafter subject to retirement by rotation and re-election at annual general meeting of the Company at least once every three years according to the provisions of the Articles, the Rules (the “**GEM Listing Rules**”) Governing the Listing of Securities on GEM of the Stock Exchange and other applicable laws.

Mr. Wu is entitled to a monthly director’s fee of HK\$20,000 and a discretionary bonus for each financial year, which is payable at the Board’s discretion and determined with reference to the Group’s results and performance for the financial year concerned. The remuneration payable to Mr. Wu was determined by the Remuneration Committee having regard to his duties and responsibilities within the Group, the Group’s remuneration policy and the prevailing market condition.

Save as disclosed above, as at the date of this announcement, Mr. Wu (i) has not held any positions with the Company or other members of the Group; (ii) has not held other directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not have any relationship with any other Directors, senior management or substantial or controlling shareholder(s) of the Company (as defined in the GEM Listing Rules); and (iv) does not have, or is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations which is required to be disclosed under Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong. Save as disclosed above and as far as the Directors are aware, there is no other information relating to the appointment of Mr. Wu as executive Director that is required to be disclosed pursuant to Rules 17.50(2) (h) to (v) of the GEM Listing Rules nor are there any other matters that need to be brought to the attention of the Shareholders and the Stock Exchange.

The Board would like to express its warm welcome to Mr. Wu in joining the Board.

## **CHANGE IN COMPOSITION OF BOARD COMMITTEE**

The Board further announces that, following the resignation of Mr. Zheng, with effect from 22 August 2023, Mr. Wu has been appointed as a member of the Remuneration Committee.

# **CHANGE OF AUTHORISED REPRESENTATIVE UNDER THE GEM LISTING RULES AND AUTHORIZED REPRESENTATIVE UNDER THE COMPANIES ORDINANCE**

The Board further announces that, with effect from 22 August 2023:

- (i) Mr. Zheng has ceased to be an authorised representative of the Company under Rule 5.24 of the GEM Listing Rules and an authorized representative of the Company to accept service of process or notice on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the laws of Hong Kong) (the “**Companies Ordinance**”); and
- (ii) Mr. Lam Williamson, being the company secretary of the Company, has been appointed as an authorised representative of the Company under Rule 5.24 of the GEM Listing Rules and an authorized representative of the Company to accept service of process or notice on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance.

By order of the Board  
**Good Fellow Healthcare Holdings Limited**  
**Ng Chi Lung**  
*Chairman and Executive Director*

Hong Kong, 22 August 2023

*As at the date of this announcement, the Board comprises Mr. Ng Chi Lung and Mr. Wu Qiyou as executive Directors; and Ms. Wong Ka Wai, Jeanne, Dr. Lam Huen Sum and Mr. Lau Tak Kei Arthur as independent non-executive Directors*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) on the “Latest Listed Company Information” page of the website of the Stock Exchange for at least seven days from the date of its publication and on the website of the Company at [www.gf-healthcare.com](http://www.gf-healthcare.com).*